Ben-Gurion University of the Negev

EyeYon Medical Appoints Dr. Sharon Bakalash MD, PhD As Chief Medical Officer

Retrieved on: 
Tuesday, February 22, 2022
Ophthalmology, Strategic planning, Weizmann Institute of Science, NES, Research, Novartis, Medicine, Safety, Consultant, Alcon, Personality, Science, Biotechnology, Ben-Gurion University of the Negev, Leadership, FDA, Harvard University, Professional, MD, CEO, Doctor of Philosophy, Pharmaceutical industry, Medical device, Northeastern University, Neuroimmunology

NES ZIONA, Israel, Feb. 22, 2022 /PRNewswire/ -- EyeYon Medical, a leading start-up company that develops innovative ophthalmic medical devices, announces Dr. Bakalash as Chief Medical Officer of EyeYon Medical .

Key Points: 
  • NES ZIONA, Israel, Feb. 22, 2022 /PRNewswire/ -- EyeYon Medical, a leading start-up company that develops innovative ophthalmic medical devices, announces Dr. Bakalash as Chief Medical Officer of EyeYon Medical .
  • Dr. Bakalash is a seasoned biotechnology entrepreneur and an ophthalmic surgeon with more than two decades of demonstrated leadership in business, science, and medicine.
  • I've known Sharon for years and her experience, professionalism, and personality is a perfect match for EyeYon Medical's multi-talented team."
  • Dr. Bakalash was a part of the Harvard University Office of Technology Development ( http://otd.harvard.edu/ ), out-licensing innovations stemming from the medical school.

EyeYon Medical Appoints Dr. Sharon Bakalash MD, PhD As Chief Medical Officer

Retrieved on: 
Tuesday, February 22, 2022
Ophthalmology, Strategic planning, Weizmann Institute of Science, NES, Research, Novartis, Medicine, Safety, Consultant, Alcon, Personality, Science, Biotechnology, Ben-Gurion University of the Negev, Leadership, FDA, Harvard University, Professional, MD, CEO, Doctor of Philosophy, Pharmaceutical industry, Medical device, Northeastern University, Neuroimmunology

NES ZIONA, Israel, Feb. 22, 2022 /PRNewswire/ -- EyeYon Medical, a leading start-up company that develops innovative ophthalmic medical devices, announces Dr. Bakalash as Chief Medical Officer of EyeYon Medical .

Key Points: 
  • NES ZIONA, Israel, Feb. 22, 2022 /PRNewswire/ -- EyeYon Medical, a leading start-up company that develops innovative ophthalmic medical devices, announces Dr. Bakalash as Chief Medical Officer of EyeYon Medical .
  • Dr. Bakalash is a seasoned biotechnology entrepreneur and an ophthalmic surgeon with more than two decades of demonstrated leadership in business, science, and medicine.
  • I've known Sharon for years and her experience, professionalism, and personality is a perfect match for EyeYon Medical's multi-talented team."
  • Dr. Bakalash was a part of the Harvard University Office of Technology Development ( http://otd.harvard.edu/ ), out-licensing innovations stemming from the medical school.

Medigus: Charging Robotics and Ben-Gurion University to Develop the Next Generation of Wireless Charging System for Electric Vehicles

Retrieved on: 
Tuesday, February 15, 2022
Carbon, Dell EMC, Lockheed, CEO, PayPal, Department, Exact sciences, Deutsche Telekom, SEC, VP, Solution, Transport, Private Securities Litigation Reform Act, Digital, Ownership, GLOBE, Technology, Student, Incubator, Computer engineering, Ben-Gurion University of the Negev, New England Fuel Institute, EV, Fuel, Electricity, BGN, Senior, Knowledge, Entrepreneurship, Invention, Research, Growth, MDGS, Rocky Mountain Institute, University, Wired (magazine), Rocky, Robotics, Industry, Mobile phone, Satellite navigation device, Pharmaceutical industry

Tel Aviv, Israel, Feb. 15, 2022 (GLOBE NEWSWIRE) -- Medigus Ltd. (Nasdaq: MDGS), a technology company engaged in advanced medical solutions, innovative internet technologies and electric vehicle and charging solutions, announced today that its wholly-owned subsidiary, Charging Robotics Ltd. and BGN Technologies, the technology transferred company of Ben-Gurion University signed an agreement to develop the next generation of Charging Robotics' wireless charging system for electric vehicles.

Key Points: 
  • Last July, Charging Robotics successfully demonstrated its ability for wireless charging at low power.
  • The development of the new system will be carried out by Prof. Alon Kuperman's research group at Ben-Gurion University.
  • The electric vehicle revolution will require advanced public charging solutions, said Hovav Gilan, CEO of Charging Robotics.
  • Charging Robotics is developing an automatic wireless charging system dedicated to public parking lots.

New Greentech Start-Up, Refhuel, to Develop Reversible Fuel Cell Technology

Retrieved on: 
Monday, February 7, 2022
Alternative Energy, Energy, Hydrogen, Electrochemistry, Tel Aviv Stock Exchange, Hydrogen economy, Department, Multimedia, TASE, Ben-Gurion University of the Negev, Time, Los Alamos National Laboratory, Doctor of Philosophy, Research, Leadership, Student, Technology, Geothermal Development Company, Chemical engineering, University, Joel Rifkin, CEO, Singapore International Energy Week, DCMA, Climate change, BIRAD, Bar-Ilan University, Associate, Invention, Renewable energy, Pharmaceutical industry, Chemistry

A new business, Refhuel, which will focus on reversible fuel cell technology launches today.

Key Points: 
  • A new business, Refhuel, which will focus on reversible fuel cell technology launches today.
  • The pioneering technology to allow reversible fuel cells, which is already in development, has been worked on at Bar-Ilan University in Israel under the leadership of Professor Lior Elbaz.
  • Refhuel is developing a reversible fuel-cell based on a proprietary hydrogen carrier technology that will enable efficient storage and production of energy.
  • We have passed the proof of concept stage and, in time, the technology has the potential to revolutionize energy storage and production.

Gamida Cell Announces Appointment of Anat Cohen-Dayag and Naama Halevi-Davidov to its Board of Directors

Retrieved on: 
Monday, January 31, 2022
Oncology, Health, Genetics, Other Health, General Health, Biotechnology, NK, KLTR, Leadership, Economics, Patient, Lymphatic system, Audit committee, Weizmann Institute of Science, Cell, Computational biology, Twitter, Immunotherapy, Certified Public Accountant, Board of directors, Board, Cancer, Instagram, Facebook, Business administration, Company, Financial compensation, Compugen, Ben-Gurion University of the Negev, Head, LinkedIn, Hematology, Nasdaq, NAM, Management, Biology, Accounting, Tel Aviv University

Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for cancer and other serious diseases, today announced the addition of Anat Cohen-Dayag, Ph.D., and Naama Halevi-Davidov, Ph.D., to its Board of Directors as Class II Directors.

Key Points: 
  • Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for cancer and other serious diseases, today announced the addition of Anat Cohen-Dayag, Ph.D., and Naama Halevi-Davidov, Ph.D., to its Board of Directors as Class II Directors.
  • Dr. Anat Cohen-Dayag has over 25 years of experience in the biotech industry, both in R&D and executive leadership roles.
  • Dr. Cohen-Dayag is President and Chief Executive Officer and a member of the Board of Directors of Compugen Ltd.
  • For additional information, please visit www.gamida-cell.com or follow Gamida Cell on LinkedIn , Twitter , Facebook or Instagram at @GamidaCellTx.

­­Impact NRS LLC Creates RumenEra Inc to Develop and Commercialize High-Impact Rumen Microbiome Applications in a Joint Collaboration with National Institute for Biotechnology in the Negev and the Agricultural Research Organization.

Retrieved on: 
Friday, January 14, 2022
Agricultural Research Organization, Volcani Center, Research, Carbon, International, Biotechnology, NEW, Population growth, Metabolic disorder, Nutrient, Edible, UNESCO, Animal, Infection, Degenerative disease, Efficiency, Environment, Data science, Genetic, Institute, Ben-Gurion University of the Negev, Technology, Publication, Social, National Institute for Biotechnology and Genetic Engineering, ARO, Biophysical environment, Multimedia, Ruminant, Social Security Government Pension Offset, Organization, Partnership, Meat, ESG, State, Food, Solution, Farmer, Leadership, National Institute, Health, Time, Water, Hand, Autoimmunity, Cancer, Genetic disorder, Milk, CEO, NRS, Goal, Cattle, Agriculture, Patent, Metabolism, Life, University, Renewable energy, Management, Pharmaceutical industry, Earth

On the other hand, milk is a major source of protein and other nutrients, which are critical for both the young and elderly worldwide.

Key Points: 
  • On the other hand, milk is a major source of protein and other nutrients, which are critical for both the young and elderly worldwide.
  • To confront these challenges, RumenEra uses microbiome-guided strategies to meet its objectives of balancing nutritional security with environmental burden, while maintaining high economic value.
  • Through its operating subsidiaries, Impact NRS is at the forefront of the life and earth sciences, including oncology diagnostics, data science, gene-editing, microbiome, and agri-tech.
  • Impact NRS LLC is headquartered inNew York City, with innovation labs and offices inIsrael, New York, New Jersey, Canada, and Japan.

DGAP-News: Biomedical AI entrepreneur Prof. Amir Geva appointed CSO of SleepX

Retrieved on: 
Tuesday, January 11, 2022
History of the Technion – Israel Institute of Technology, Biomedical engineering, Research, Technology, IEEE, Israeli Navy, Electricity, Doctor of Science, Sleep apnea, Biomedicine, Elbit Systems, CEO, Machine learning, Solution, OTC, Israeli Air Force, Computer, Sleep, General Data Format for Biomedical Signals, AI, DreamIt Ventures, Ben-Gurion University of the Negev, Data analysis, Senior, Snoring, Medical device, Pharmaceutical industry

SleepX, a subsidiary of AppYea (OTC: APYP) focusing on the development of accurate wearable monitoring solutions to treat sleep apnea and snoring, announced today the appointment of Biomedical AI entrepreneur Prof. Amir Geva, as its chief science officer.

Key Points: 
  • SleepX, a subsidiary of AppYea (OTC: APYP) focusing on the development of accurate wearable monitoring solutions to treat sleep apnea and snoring, announced today the appointment of Biomedical AI entrepreneur Prof. Amir Geva, as its chief science officer.
  • Prof. Geva is a world-renowned expert in the field of machine learning, with over 25 years of business leadership experience as the founder and R&D teams leader of biomedical AI companies Elminda, InnerEye and WideMed.
  • As of today, Prof. Geva had published 62 scientific articles, and he is Senior Member at the Biomedical Engineering and Computers of the IEEE.
  • "SleepX' is the right solution many had been waiting for", Prof. Amir Geva commented.

DGAP-News: AppYea completes acquisition of SleepX, entering a $6-9 billion sleep treatments market: expects to begin marketing during 2H2022

Retrieved on: 
Friday, December 31, 2021
Diagnosis, Machine learning, Global, Snoring, Brain, U.S. Securities and Exchange Commission, CAGR, Investment, IP, AI, Quality of life, Solution, Smartphone, Sleep, Calibration, Anomaly, OTC, USD, Ben-Gurion University of the Negev, Research, Marketing, Vital signs, Security (finance), Technology, Acquisition, Time, Sleep apnea, Biomedicine, Sale, Negev, Pharmaceutical industry, Medical device, DreamIt Ventures, EU

AppYea completes acquisition of SleepX, entering a $6-9 billion sleep treatments market: expects to begin marketing during 2H2022

Key Points: 
  • AppYea completes acquisition of SleepX, entering a $6-9 billion sleep treatments market: expects to begin marketing during 2H2022
    The issuer is solely responsible for the content of this announcement.
  • After the acquisiiton, SleepX will continue operating under its own brand name as a fully owned AppYea subsidiary.
  • The merged company will focus on further development and commercialization of SleepX's solution, including continued R&D investments and new initiatives in sales and marketing.
  • Meanwhile, we are examining the acquisition of other synergetic activities that will complement the SleepX vision to improve sleep quality and quality of life globally.'

BGN Technologies and Oazis Accelerator Establish DOTS, Developer of a Revolutionary Soil Nitrate Monitoring System for Agricultural Use

Retrieved on: 
Tuesday, December 14, 2021
Solution, Incubator, CEO, Deutsche Telekom, Ben-Gurion University of the Negev, BGU, PayPal, Technology, Soil, Efficiency, Drinking water, Department, Lockheed, General partnership, Lists of companies, Nitrate, Growth, Computer engineering, Agriculture, Nutrient, Reliance Industries, Groundwater, Forbes Global 2000, Dell EMC, DOTS, INR, Farmer, Marketing, Student, Research, Water, Program, Senior, University, LinkedIn, Water resources, Electricity, Fertilizer, Portrait, OurCrowd, Fortune Global 500, Multinational corporation, Entrepreneurship, The Zuckerberg Institute for Water Research, Doctor of Philosophy, Reliance, Industry, BGN, Fortune 500, Mentorship, Israel Innovation Authority

BEER-SHEVA, Israel, Dec. 14, 2021 /PRNewswire/ -- BGN Technologies , the technology transfer company of Ben-Gurion University of the Negev (BGU), announced the establishment of DOTS, developer of a new nitrate monitoring system for continuous real-time monitoring of nitrate levels in the soil for agricultural use.

Key Points: 
  • BEER-SHEVA, Israel, Dec. 14, 2021 /PRNewswire/ -- BGN Technologies , the technology transfer company of Ben-Gurion University of the Negev (BGU), announced the establishment of DOTS, developer of a new nitrate monitoring system for continuous real-time monitoring of nitrate levels in the soil for agricultural use.
  • Our new technology, which enables real-time monitoring of soil nitrate levels, can supply farmers with valuable data on nutrient availability for their crops.
  • Its ability to continuously monitor soil nitrate levels produces a highly detailed portrait of the rapidly changing concentrations of nitrate in the soil.
  • BGN Technologies brings technological innovations from the lab to the market and fosters research collaborations and entrepreneurship among researchersand students.

Helius Medical Technologies, Inc.’s Dr. Antonella Favit-Van Pelt to Present at 4th International Brain Stimulation Conference on December 9

Retrieved on: 
Monday, December 6, 2021
Patient, Lists of diseases, News, MGH Institute of Health Professions, TEP, Sale, Conference, Private Securities Litigation Reform Act, Forward-looking statement, Company, MS, Multiple sclerosis, Tongue, Elsevier, Stanford University, International Brain Research Organization, Doctor of Philosophy, Pons, Nasdaq, Research, GLOBE, Neuromuscular Disorders, FDA, Securities and Exchange Commission (Philippines), Ben-Gurion University of the Negev, Traumatic brain injury, Movement disorders, HSDT, Gait, Drug development, Stroke, Medical device

The conference is organized by Elsevier, a global leader in information and analytics, and brings together experts in the field of brain stimulation across a wide range of disciplines.

Key Points: 
  • The conference is organized by Elsevier, a global leader in information and analytics, and brings together experts in the field of brain stimulation across a wide range of disciplines.
  • Alongside three other key opinion leader clinicians, Dr. Favit-Van Pelt will be part of a Thursday symposium titled Recently authorized by the FDANovel Brain Stimulation treatments coming to a clinic near you.
  • Dr. Favit-Van Pelt is a rare disease expert and pioneer in the field of applied theragnostics for the development of disease-modifying treatments.
  • Dr. Favit-Van Pelt currently serves as Chief Medical Officer of Helius.